Vitamin B12 levels in familial mediterranean fever patients treated with colchicine

Simple item page
dc.contributor.authorGemici A.I.
dc.contributor.authorSevindik O.G.
dc.contributor.authorAkar S.
dc.contributor.authorTunca M.
dc.date.accessioned2024-07-22T08:18:09Z
dc.date.available2024-07-22T08:18:09Z
dc.date.issued2013
dc.description.abstractObjectives. Familial Mediterranean fever (FMF) is an autosomal recessive autoinflammatory disease characterised by paroxysmal attacks of serosal inflammation. Colchicine is highly effective in preventing these attacks but it may also disrupt the intestinal absorption of vitamin B12. We hypothesised that patients treated with colchicine for a prolonged period could develop deficiency of the vitamin. Methods. Ninety-five adult FMF patients on regular colchicine treatment for at least 2 years and age and sex-matched 90 healthy controls were enrolled and complete blood count with platelets, vitamin B12 and folic acid were measured in each person. We also investigated 15 adult FMF patients who were not yet on colchicine. Results. The mean vitamin B12 values were not significantly different between the groups (352.12 (SD=171.62) pg/mL vs. 360.96 (SD=146.53) pg/mL, p=0.71), but there were significantly more vitamin B12 deficient cases among FMF patients (12 vs. 3; p=0.021) and 3 out of these 12 had megaloblastic anaemia. None of the vitamin B12 deficient controls had anaemia. We could not identify any disorder which might have causative effect for the deficiency among this subgroup. The mean vitamin B12 value of 15 colchicine-naïve cases was not significantly different from patients on colchicine (p=0.356). Conclusion. We did not observe significant vitamin B12 deficiency among colchicine-treated FMF patients but some cases may be more prone to developing this potentially serious disorder. © Clinical and Experimental Rheumatology 2013.
dc.identifier.issn1593098X
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17213
dc.language.isoEnglish
dc.subjectAdult
dc.subjectCase-Control Studies
dc.subjectChi-Square Distribution
dc.subjectColchicine
dc.subjectFamilial Mediterranean Fever
dc.subjectFemale
dc.subjectHumans
dc.subjectImmunosuppressive Agents
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectTime Factors
dc.subjectTreatment Outcome
dc.subjectVitamin B 12
dc.subjectVitamin B 12 Deficiency
dc.subjectcolchicine
dc.subjectcyanocobalamin
dc.subjectfolic acid
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectblood cell count
dc.subjectcontrolled study
dc.subjectcyanocobalamin deficiency
dc.subjectdisease predisposition
dc.subjectfamilial Mediterranean fever
dc.subjectfemale
dc.subjectfolic acid blood level
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmegaloblastic anemia
dc.subjectpriority journal
dc.subjectthrombocyte count
dc.subjectvitamin blood level
dc.titleVitamin B12 levels in familial mediterranean fever patients treated with colchicine
dc.typeArticle

Files

Collections

Scopus Koleksiyonu